Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
Date:6/1/2009

CALGARY, June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung were presented May 30, 2009 at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting is being held in Orlando, Florida from May 29 to June 2, 2009.

The presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" was delivered by Dr. Monica Mita, the study principal investigator at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The interim results demonstrate that the treatment has been well tolerated, with 15 of 36, or 42% of evaluable patients experiencing stable disease (SD) for more than 16 weeks, including five patients who have had SD for more than 24 weeks. One patient had SD for more than 80 weeks. Oncolytics reported on May 12, 2009, that full enrolment of 52 patients was completed, at which time nine patients were continuing on study.

"The ASCO data are very encouraging, both in terms of efficacy in patients with sarcoma, and in those with other tumor histologies in whom the IDD group are investigating various REOLYSIN regimens," said Dr. Frank Giles, Director, IDD, and Deputy Director, CTRC at UTHSCSA.

Additional REOLYSIN results presented

Two additional poster presentations covering positive results of REOLYSIN trials were also presented at the ASCO meeting on May 30, 2009.

Dr. Johann de Bono and colleagues delivered a poster presentation entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and Gemci
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
2. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
3. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
4. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
6. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
7. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
8. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
10. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... City, OK (PRWEB) May 24, 2013 The ... of casualties. And following its ravage, the mayor of Moore, ... bill for new houses, said a report from cnn.com. Reaching ... the tornado victims complimentary Molderizer and Safe Shield to counter ... to the report published on May 22, 2013, caused 24 ...
(Date:5/23/2013)... ROCK, Colo. , May 23, 2013 ... diagnostic company focused on obtaining FDA clearance and ... , today announced the pricing of an underwritten public ... related warrants to purchase 3,500,000 shares of its common ... at a combined public offering price of $1.25 per ...
(Date:5/23/2013)... Wis. , May 23, 2013 ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... its research opinion on the company based on ... , Non-Prescription, All Natural Product to ... the Product Outperforms #1 Prescription Competitor , ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3
... Director Nominees on the Blue Proxy Card TodayRiskMetrics ... 15 Amylin Pharmaceuticals, Inc. (Nasdaq: ... response to a report issued by RiskMetrics Group ... of Stockholders to be held on May 27, ...
... , May 15 Interleukin Genetics, Inc. (NYSE Amex: ... presenting at the BIO 2009 Business Forum on Wednesday, May ... the Sheraton Atlanta Hotel in Atlanta, GA. Lewis H. Bender, ... to include the Company,s business model, available genetic tests and ...
... Calif., May 15 Fate Therapeutics, Inc. ... intellectual property rights jointly owned by Children,s Hospital Boston ... compositions and methods for supporting hematopoietic stem cells. ... of the Stem Cell Program at Children,s Hospital Boston ...
Cached Biology Technology:Amylin Comments on RiskMetrics Report 2Amylin Comments on RiskMetrics Report 3Amylin Comments on RiskMetrics Report 4Amylin Comments on RiskMetrics Report 5Interleukin Genetics to Present at the 2009 BIO Business Forum 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3
(Date:5/22/2013)... Trial (NLST) investigators also conclude that the 20 ... computed tomography (LDCT) versus chest X-ray (CXR) screening ... achievable at experienced screening centers in the United ... share with their patients about the benefits and ... publication in the New England Journal of ...
(Date:5/22/2013)... novel technique that can detect molecular variants in chemical ... of the most important, though time-consuming, processes in analytical ... Nature , post-doctoral researcher David Patterson, Professor of ... Center for Free-Electron Laser Science (CFEL) in Hamburg, Germany ... to identify molecular variants apart, and to determine how ...
(Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... the expansion of oxygen-deficient or oxygen minimum zones (OMZs), also ... carbon is captured and sequestered on the seafloor and alter ... ocean carbon sequestration. Despite the importance of these effects, very ... how they respond to environmental changes. In the Oct. ...
... 2009 A bioethicist who specializes in moral dilemmas families ... with the first-ever March of Dimes Distinguished Lectureship in Perinatal ... John D. Lantos, MD, a nationally-recognized pediatrician and ethicist, ... Different" at the American Society of Bioethics and Humanities, 11th ...
... sex-based biological differences extend to genetic expression in cerebral ... later divergences in how our brains develop. This is ... Elena Jazin and Bjrn Reinius, which has been published ... Psychiatry . Professor Elena Jazin and doctoral student ...
Cached Biology News:Model microbial community for studying expanding dead zones characterized 2Model microbial community for studying expanding dead zones characterized 3March of Dimes establishes 2 new perinatal bioethics awards 2Sex-based prenatal brain differences found 2
...
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
Synaptic Vesicle I Sampler Kit 10g each...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
Biology Products: